PT - JOURNAL ARTICLE AU - Hu, Yuqi AU - Gao, Le AU - Zhou, Lingyue AU - Liu, Wenlong AU - Wei, Cuiling AU - Liu, Boyan AU - Sun, Qi AU - Tian, Wenxin AU - Chu, Rachel Yui Ki AU - Song, Song AU - Cheng, Franco Wing Tak AU - Chan, Joe Kwun Nam AU - Ng, Amy Pui Pui AU - Lo, Heidi Ka Ying AU - Lee, Krystal Chi Kei AU - Chang, Wing Chung AU - Wong, William Chi Wai AU - Chan, Esther Wai Yin AU - Wong, Ian Chi Kei AU - Chai, Yi AU - Lai, Francisco Tsz Tsun TI - Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study AID - 10.1101/2024.08.07.24311592 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.07.24311592 4099 - http://medrxiv.org/content/early/2024/08/08/2024.08.07.24311592.short 4100 - http://medrxiv.org/content/early/2024/08/08/2024.08.07.24311592.full AB - Background Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is unclear due to the absence of cohort studies.Methods We extracted data from a territory-wide public healthcare database in Hong Kong to build a retrospective cohort of anonymized patients aged 18+ with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90+ days, with at least two prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between clozapine and olanzapine users. The absolute rate difference was also estimated.Results In total, 9,965 patients were included, with 834 clozapine users, who had a significant IRR of 2.22 (95% CI 1.52, 3.34) for HM compared to olanzapine users. Absolute rate difference was estimated to be 57.40 (95% CI 33.24, 81.55) per 100,000 person-years. Findings were consistent across sub-groups by age and sex in terms of effect size, although the IRR was non-significant for those aged 65 or older. Sensitivity analyses all supported the robustness of the results and showed good specificity to HM but no other cancers.Conclusion Absolute rate difference in HM incidence was very small although there is a twofold elevated rate. Pharmacotherapies with clozapine may consider this potential rare risk in addition to known side effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for this study was obtained from the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB, reference number: UW 20-113).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying the results presented in the study are available from Hong Kong Hospital Authority's Central Panel on Administrative Assessment of External Data Requests (https://www3.ha.org.hk/data/Provision/Submission).